Merck & Co. (MRK)
(Delayed Data from NYSE)
$116.60 USD
+0.05 (0.04%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $116.55 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.60 USD
+0.05 (0.04%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $116.55 -0.05 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.
Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merck (MRK) Beats Q4 Earnings Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Powell Dubious on March Cut, Markets Slide
by Mark Vickery
Indices jumped higher on the Fed's release initially, but in terms of forecasting a March cut, Fed Chair Powell said that this was "not the most-likely case."
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.
Pfizer (PFE) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 152.63% and 0.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $120.82, denoting a +0.57% change from the preceding trading day.
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?
by Zacks Equity Research
With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.
What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings
by Zacks Equity Research
Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.
Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
Q4 Earnings Season Scorecard and Fresh Analyst Reports for Amazon, Home Depot & Merck
by Sheraz Mian
Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.
Merck (MRK) Laps the Stock Market: Here's Why
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $119.43, signifying a +0.45% move from its prior day's close.
Merck (MRK) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $118.49, representing a -0.12% change from its previous close.
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More
by Kinjel Shah
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VUSE